tbuckley/cabot-search huggingface dataset:
Victory
Authors: Jason David Eubanks
Journal: Annals of Internal Medicine (2012)

Ad Libitum3 July 2012VictoryJason David Eubanks, MDJason David Eubanks, MDFrom Case Medical Center, Cleveland, OH 44106.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-1-201207030-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail With so many liquid crystals—... Author, Article, and Disclosure InformationAffiliations: From Case Medical Center, Cleveland, OH 44106.Current Author Address: Jason David Eubanks, MD, 11100 Euclid Avenue, Cleveland, OH 44106; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 3 July 2012Volume 157, Issue 1Page: 68KeywordsForecastingMuscular dystrophiesMyalgiaPostural controlShouldersSweatTwinsWalking ePublished: 3 July 2012 Issue Published: 3 July 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Abstract 12302: Mortality and Readmissions After Heart Failure Hospitalization in a Community Based Cohort: Estimating Risk Using the Acute Decompensated Heart Failure National Registry (ADHERE) Classification and Regression Tree (CART) Algorithm
Authors: Sithu Win, Imad Hussain, Virginia Hebl, Margaret M Redfield
Journal: Circulation (2015)

Background: The Acute Decompensated Heart Failure National Registry (ADHERE) Classification and Regression Tree (CART) algorithm is an accepted method to assess a heart failure (HF) patient’s risk of inpatient mortality based on the patient’s systolic blood pressure (≥115 vs. &lt;115 mmHg), blood urea nitrogen (BUN; ≥43 vs. &lt;43 mg/dL), and creatinine (≥2.75 vs. &lt;2.75 mg/dL) at the time of admission. Whether the ADHERE CART algorithm identifies risk of longer term poor outcomes and is predictive in patients with systolic (EF &lt; 50%) or diastolic (EF ≥ 50%) HF in the community is unclear. Methods: We identified all hospitalizations for a primary diagnosis of HF occurring between 2000-2013 in a community-based cohort living within 40 miles of Rochester, MN. Outcomes including length of stay, in-hospital mortality, 30 and 90 day post-discharge mortality and readmission for any cause at 30 and 90 days were compared across the ADHERE CART risk groups using logistic regression for the entire cohort and separately for systolic (EF &lt; 50%) and diastolic (EF ≥ 50%) HF. Results: See Table. We examined 5,918 heart failure hospitalizations among 3,628 individual patients. Distribution of hospitalizations across the risk categories is shown in table. Length of stay, in-hospital mortality, 30 and 90 day mortality and 30 and 90 day readmission rates all increased with increasing ADHERE risk categories. Similar results were obtained separately for systolic and diastolic HF. Conclusion: The ADHERE CART algorithm is simple, uses data universally available on admission, and identifies groups that differ substantially in their post-discharge adverse outcomes regardless of HF type (systolic vs diastolic) in the community. The ADHERE CART algorithm may inform clinical decision regarding advanced HF treatments, end-of-life planning and care transition services in patients hospitalized for HF in the community.
Disparities in Drowning
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sarcoidosis
Authors: Karl W. Thomas
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC)
Authors: H. Raftopoulos, B. Escudier, G. Renshaw, P. N. Lara, J. Dutcher, D. Nanus, D. P. Petrylak, L. Sacris
Journal: Journal of Clinical Oncology (2004)

4629 Background: Indisulam (E7070) is a synthetic sulfonamide that blocks the G1/S transition of the cell cycle by inhibiting cyclin dependent kinases. We conducted an open-label, non-randomized phase II study of indisulam in patients (pts) with locally advanced and/or metastatic RCC. Methods: The primary endpoint was progression free survival (PFS); secondary endpoints included response rate, median survival and safety. Eligibility included: ≥ 18 years of age, KPS ≥ 70% with evidence of progression in the previous 3 months. Only one prior immunotherapy regimen was allowed. Response was independently evaluated per RECIST guidelines. Pts received indisulam 700 mg/m2 over one hr q 3 weeks until progression or unacceptable toxicity. Results: Thirty pts were treated (9 F, 21 M). Median age was 60 years (range 39–82). Pts received a median of 2 cycles (range 1–10); 5 pts continued therapy for > 4 cycles. 20 of 30 pts discontinued therapy due to disease progression. Results presented are based on available data from 28 pts. Prior treatments were: nephrectomy (27 pts), radiotherapy (7 pts), prior systemic therapy (24 pts): various cytokine regimens (with 5FU in 1 pt), thalidomide, all-trans retinoic acid, 13 cis-retinoic acid, SU5416, R115777, Neovastat. Lesions followed included those involving lung, kidney, adrenals, soft tissues, bone, lymph nodes, and liver. Attributable adverse events were reported in 57% of patients, of which 43% were CTC Grade 3 or 4. These included: hyperglycemia (3), myocardial infarction (1), acute renal insufficiency (1), prolonged prothrombin time (1), hyperbilirubinemia (1), sepsis (1), death, cause unknown (1) and aphasia (1). Two events of febrile neutropenia have been reported. Two patients required a dose reduction for neutropenia. CTC Grade 1/2 infusion site reactions have been observed in 4 patients. Although efficacy analysis is ongoing, the majority of pts discontinued therapy due to progression; thus, the number of cycles delivered reflected PFS. Conclusions: Indisulam is well-tolerated in patients with renal cell carcinoma, efficacy analysis is continuing. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eisai Pharmaceuticals Eisai Medical Research
CREMATION GROWING IN FAVOR.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mechanistic Aspects of Ingested Chlorine Dioxide on Thyroid Function: Impact of Oxidants on Iodide Metabolism
Authors: J. Peter Bercz, Lillian L. Jones, Robert M. Harrington, Rohit Bawa, Lyman Condie
Journal: Environmental Health Perspectives (1986)

Toxicological studies dealing with recent findings of health effects of drinking water disinfectants are reviewed. Experiments with monkeys and rodents indicate that the biological activity of ingested disinfectants is expressed via their chemical interaction with the mucosal epithelia, secretory products, and nutritional contents of the alimentary tract. Evidence exists that a principal partner of this redox interaction is the iodide of nutritional origin that is ubiquitous in the gastrointestinal tract. Thus the observation that subchronic exposure to chlorine dioxide (ClO2) in drinking water decreases serum thyroxine levels in mammalian species can be best explained with changes produced in the chemical form of the bioavailable iodide. Ongoing and previously reported mechanistic studies indicate that oxidizing agents such as chlorine-based disinfectants oxidize the basal iodide content of the gastrointestinal tract. The resulting reactive iodine species readily attaches to organic matter by covalent bonding. Evidence suggests that the extent to which such iodinated organics are formed is proportional to the magnitude of the electromotive force and stoichiometry of the redox couple between iodide and the disinfectant. Because the extent of thyroid uptake of the bioavailable iodide does not decrease during ClO2 ingestion, it seems that ClO2 does not cause iodide deficiency of sufficient magnitude to account for the decrease in hormonogenesis. Absorption of one or more of iodinated molecules, e.g., nutrients, hormones, or cellular constituents of the alimentary tract having thyromimetic or thyroid inhibitory properties, is a better hypothesis for the effects seen.
Abstract 3873: CHOP10/TRB3/Akt signaling regulates ER stress apoptosis in colon cancer cells treated with prostamide-J
Authors: Hussam Albassam, Daniel A. Ladin, Rukiyah Van Dross
Journal: Cancer Research (2019)

Abstract The endoplasmic reticulum (ER) is a cellular organelle that is primarily responsible for oxidative protein folding. When the protein folding load in cells exceeds the protein folding capacity, ER stress occurs. The ER stress pathway is a prominent regulator of cancer cell death and as a result, ER stress inducers are being exploited pharmacologically. Cytotoxic ER stress is typically regulated by the transcription factor, C/EBP homologous protein 10 (CHOP10). Transcriptional products of CHOP10 include pro-apoptotic genes, such as tribbles-related protein 3 (TRB3), death receptor-5 (DR5), and ER oxidoreductase 1α (ERO1α). Our previous data showed that apoptosis mediated by 15deoxy, Δ12,14 prostamide J2 (15dPMJ2) occurred in an ER stress-dependent manner. However, the signaling pathway that regulates 15dPMJ2 mediated ER stress apoptosis has not been identified. Therefore, the goal of this study is to determine the role of CHOP10 and its transcriptional targets in ER stress apoptosis that is induced by 15dPMJ2 in colon cancer cells. According to our data, 15dPMJ2 was 3-fold more effective in inducing apoptosis in the human colon cancer cell line, HCT116, compared to the non-tumorigenic colon cell line, FHC. The induction of apoptosis in HCT116 cells occurred coincident with a significant increase in CHOP10 protein expression. In addition, blockade of the ER stress pathway with 4-phenylbuterate (PBA) or salubrinal prevented apoptosis indicating that cell death is reliant upon ER stress. To determine the role of CHOP10 in this process, CRISPR/Cas9 CHOP10 knockout HCT116 cells (CHOP10-KO-HCT116) were generated. As anticipated, 15dPMJ2 increased CHOP10 expression in wt-HCT116 cells but not in CHOP10-KO-HCT116 cells. Furthermore, 15dPMJ2 increased the expression of ERO1α, DR5, TRB3, and it induced apoptosis in wt-HCT116 cells, but not in CHOP10-KO cells. Interestingly, the induction of TRB3, but not DR5 or ERO1α, was completely inhibited in cells devoid of CHOP10 expression. Therefore, the activity of protein kinase B (PKB)/Akt, a known TRB3 target, was investigated. CHOP10 stimulation by 15dPMJ2 inactivated Akt in wt-HCT116 cells, but not in CHOP10-KO cells. These findings suggest the importance of CHOP10, TRB3, and Akt in the control of the ER stress-mediated apoptosis in response to 15dPMJ2 treatment. Thus, 15dPMJ2 is a potential chemotherapeutic agent that inhibits PKB/Akt survival signaling by upregulating the CHOP10/TRB3 pathway to prevent colon cancer growth. Citation Format: Hussam Albassam, Daniel A. Ladin, Rukiyah Van Dross. CHOP10/TRB3/Akt signaling regulates ER stress apoptosis in colon cancer cells treated with prostamide-J [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3873.
QUANTITATIVE ASSESSMENT OF MYOCARDIAL PERFUSION IN THE DETECTION OF SIGNIFICANT CORONARY ARTERY DISEASE: CUT-OFF VALUES AND DIAGNOSTIC ACCURACY OF QUANTITATIVE H215O PET IMAGING
Authors: Ibrahim Danad, Valtteri Uusitalo, Tanja Kero, Antti Saraste, Pieter Raijmakers, Adriaan Lammertsma, Martijn Heymans, Sami Kajander, Mikko Pietil, Stefan James, Jens Srensen, Paul Knaapen, Juhani Knuuti
Journal: Journal of the American College of Cardiology (2014)
The gamma knife
Authors: R. N. Kjellberg
Journal: JAMA (1988)

<h3>To the Editor. —</h3> In the May 6 letters, the authors of "The Gamma Knife" make some inappropriate and misleading comparisons with proton-beam therapy.<sup>1</sup> X-ray and gamma radiation are both electromagnetic radiation and thus are different physical species from protons and other heavy particles with mass and electric charge. X-ray has been in use since the turn of the century and was used in treatment of arteriovenous malformations (AVMs) since the late 1920s. A good number of reports during the years attest that it is of no or limited effectiveness in treating AVMs. Gamma radiation differs from x-ray only in the range of its wave length and frequency. Gamma radiation from cobalt 60 began to be used in the mid-1950s and has been used with decreasing frequency since the early 1970s. On the other hand, we have been using the proton beam increasingly since the early 1960s. The Bragg
The Practice of Medicine
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fetal and infant growth and impaired glucose tolerance.
Journal: BMJ (1991)

cases,' but what is not mentioned is the delay in arriving at that diagnosis.Shafer investigated the histopathology request forms for 779 cases of oral cancer and found a significant delay in diagnosis in 15% of cases.4The author admitted that this was probably an underestimate in view of inadequate details often given on these forms.This has been a concern to us because we have gained the clinical impression that incorrect diagnosis and delayed referral of patients with oral cancer by practitioners are still prevalent.We recently audited practitioners' referrals of 96 patients with estabhshed oral cancer.Medical practitioners had made an incorrect or no diagnosis in 48% of referral letters.In cases of regional lymphadenopathy the proportion with an incorrect or no diagnosis fell to 32%.Delays in referral were identified in 36% of cases, the median delay being four weeks (range one week to eight months).The results for dental practitioners were worse.It is fundamental that in cases of tumour the diagnosis must be considered before excision and that a correct technique is used.A high index of suspicion is required, and postgraduate education is essential to instil this.Until diagnostic ability improves it seems preferable for all cases of suspicious skin lesions to be referred to a con- sultant.The advice for oral cancer is that all cases should be referred for assessment before biopsy.The support for practitioners providing a biopsy service because of hospital waiting times is un- tenable2 as patients with cancer should bypass waiting lists.
Climate change—the wider threat
Authors: None The Lancet Planetary Health
Journal: The Lancet Planetary Health (2017)

When the subject of climate change is raised, people tend to think of extreme heat events, droughts, violent storms, rising sea levels, and floods. Today, we certainly live in an era of severe weather events, which will intensify if human-driven climate change continues unabated. Such events are known to exert a great physical toll on people worldwide through injury, displacement, and death. However, little attention has been paid to the psychological impacts that widespread changes in climatic conditions can cause.
Continuing education courses for physicians for the period Sept 1, 1979, through Aug 31, 1980
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEDICAL STUDENTS AND THE SELECTIVE SERVICE
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BIOCHEMICAL BREAK-THROUGH
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal